Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
6 citing papers in PubMed.
Specific FbioRxiv : the preprint server for biology · 2026
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Sofia La VecchiaDepartment of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.ORCID 0009-0001-7236-129X
Saurav DoshiDepartment of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.ORCID 0000-0002-1081-0969
Petros AntonoglouDepartment of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.ORCID 0009-0007-5079-0572
Tanima KunduDepartment of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.ORCID 0000-0001-8129-6912
Wafa Al SantliDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Kleopatra AvrampouDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Matthew T WitkowskiDepartment of Pediatrics Hematology/Oncology/Bone Marrow Transplant, University of Colorado, Anschutz Medical Campus, Aurora, CO 13123, USA.ORCID 0000-0003-1434-4288
Anna PellattieroVeneto Institute of Molecular Medicine, Padua 35129, Italy.ORCID 0000-0002-9793-3493
Christina GlytsouDepartment of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.ORCID 0000-0002-6260-338X
Funding
Translational Research Support CoreP30ES005022 · NIEHS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI HELMUT ZARBL · 1988 to 2026
$47.4M
Targeting an RNA Binding Protein Network in Acute Myeloid LeukemiaR01CA242020 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ABDEL-WAHAB, OMAR, AIFANTIS, IANNIS · 2020 to 2024
$2.7M
Regulation of emergency hematopoiesis by the ubiquitin-proteasome systemR01HL159175 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI AIFANTIS, IANNIS, BUSINO, LUCA · 2021 to 2024
$2.5M
The role of inflammation in the regulation of immune response in acute myeloid leukemiaR01CA283574 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Iannis Aifantis, Ann-Kathrin Eisfeld · 2023 to 2026
$2.3M
PI3 Kinase Inactivation in Myelodysplastic SyndromeR01DK130895 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI GRITSMAN, KIRA · 2022 to 2025
$2.2M
PI3K Isoform Dependence in Adult Hematopoiesis and Myeloid LeukemiaR01CA196973 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI GRITSMAN, KIRA · 2016 to 2020
$2.0M
Targeting mitochondrial dynamics in drug-resistant acute myeloid leukemiaR00CA252602 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI GLYTSOU, CHRISTINA · 2023 to 2025
$747k
Beckman Coulter MoFlo Astrios EQ Cell SorterS10OD026876 · OD · RUTGERS, THE STATE UNIV OF N.J. · PI LASKIN, DEBRA L · 2019 to 2019
$504k
Targeting mitochondrial dynamics in drug-resistant acute myeloid leukemiaK99CA252602 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GLYTSOU, CHRISTINA · 2020 to 2021
$306k
Role of the Class IA PI3K in Hematopoietic Stem Cell Self-RenewalF32HL146119 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI AMES, KRISTINA · 2019 to 2022
$213k
PI3 Kinase Inactivation in Myelodysplastic SyndromeR56DK130895 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI GRITSMAN, KIRA · 2021 to 2021
Acute myeloid leukemia (AML) is the most prevalent and deadliest adult leukemia. Its frontline treatment uses the BH3 mimetic venetoclax to trigger mitochondria-dependent apoptosis. However, drug resistance nearly always develops, calling for therapies to circumvent it. Advanced microscopy and genome-wide CRISPRi screen analyses pinpointed mitochondrial adaptations primarily mediated by the master regulator of cristae shape optic atrophy 1 (OPA1) as critical for BH3 mimetics resistance. Resistant AML cells up-regulate OPA1 to modify their mitochondrial structure and evade apoptosis. MYLS22 and Opitor-0, two specific and nontoxic OPA1 inhibitors, promote apoptotic cristae remodeling and cytochrome
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Small-molecule OPA1 inhibitors reverse mitochondrial adaptations to overcome therapy resistance in acute myeloid leukemia. · full record | OpenQuestion